

## Investor briefing – Philips update

---

**30 September 2024**

**Melbourne, Australia, 30 September 2024:** 4DMedical Limited (ASX: 4DX, “4DMedical”, or the “Company”), a leader in respiratory imaging technology, is pleased to invite shareholders, investors and interested parties to its investor webinar hosted by the Managing Director and Chief Executive Officer, Dr Andreas Fouras.

4DMedical will hold an investor webinar on **Tuesday, 1 October 2024 at 11am AEST**, where Dr Andreas Fouras will provide an update on the Company’s recent announcements.

### Investor Webinar Registration Details

An investor webinar with Dr Andreas Fouras, Managing Director and Chief Executive Officer of 4DMedical will be held at 11am AEST on Tuesday, 1 October 2024.

Please register in advance using the following links:

Phone registration: <https://s1.c-conf.com/diamondpass/10042387-72geyr.html>

Webcast: <https://ccmediaframe.com/?id=spqX9wIz>

After registering, you will receive a confirmation email containing information about joining the webinar or dial-in details for those who would prefer to join by telephone.

–ENDS–

Authorised by the 4DMedical Board of Directors.

### Contacts

#### Corporate

Chief Financial Officer  
Simon Glover  
[sglover@4dmedical.com](mailto:sglover@4dmedical.com)

#### Administration

Company Secretary  
Naomi Lawrie  
[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

#### Media Enquiries

[4dmedia@4dmedical.com](mailto:4dmedia@4dmedical.com)

### About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.



XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio's regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity and more personalised care for patients.

To learn more, please visit [www.4dmedical.com](http://www.4dmedical.com) and [www.imbio.com](http://www.imbio.com)